

Lung service profiles – a short overview

Sean McPhail
Senior Analyst & Profiles Technical Lead



Discuss...




Using information to improve quality & choice

Lung service profiles: rationale, process, structure

Specialist lung profiles (briefly): going forward

A PERIODIC TABLE OF VISUALIZATION METHODS



Process Visualization Note: Depending on your location and connection speed it can take some time to load a pop-up picture.

>**☆**<

Fd

© Ralph Lengler & Martin J. Eppler, www.visual-literacy.org

Structure Visualization

Overview п Detail

> <

0 Detail AND Overview

< > Divergent thinking

Convergent thinking

>#< >☆< > 位 < >@< <=> Su Pc St H٥ OC. house of

game board

performance strategy map organisation supply demand cur charting chart 故 故 >@< >0< Pf Sg EG Μz portfolio strateric mintzberg's edgeworth

feedback quality diagram <(0)> <=> Z Ad zwicky's organigraph diagram

Ft Ma failure tree quadrant >#< Bm 0.6 decision

discovery

>#<

bcg matrix

Ld life-cycle diagram >#< Stc

strategy

>#<

>#< Po porter's five forces >#<

value chain

<m> s-cycle <=> >#<

Hy

hype-cycle

0 >#< Sm Is stakeholder

map

Sr

stakeholder

rating map

Tc ishikawa technology roadmap diagram >#< <=> Ta Sd taps spray

version 1.5

₩

diagram


http://www.visual-literacy.org/periodic_table/periodic_table.html


diagram


box


For example...











Profiles...



			1		Percenta	ge or rate		Tr	ust rate or percentage compared to Eng	and	l	
Section	#	Indicator	No. of patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41	• •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	329				191	1	•	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				10	0	•0	31	NLCA	2011
	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%	•	75%	NCDR	2010
(0	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%	•	100%	NCDR	2010
Demographics (based on newly gnosed patients, 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%	•	46%	NCDR	2010
hic ewl nts,	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	→ 0	34%	NCDR	2010
rap on n atiei	8	Male patients (from #1)	161	53%	47%	58%	55%	43%	0 •	72%	NCDR	2010
ed o	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	•	100%	NLCA	2011
bas bas	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%	• •	68%	NLCA	2011
co co	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%	0	30%	NLCA	2011
ਰ	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%	•	80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%	0	100%	NLCA	2011
	14	Peer review: Does the specialist team have full membership? (3)	SA	Yes							NCPR	2010/11
Specialist	15	Peer review: Proportion of peer review indicators met	SA	85%			89%				NCPR	2010/11
Team	16	Peer review: are there immediate risks? (4)	SA	No							NCPR	2010/11
ream	17	Peer review: are there serious concerns? (4)	SA	No							NCPR	2010/11
	18	Number and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	79%	0%	○ ◆	100%	NLCA	2011
	19	Number of urgent GP referrals for suspected cancer	406				293	0	•••	853	CWT	2010/11
	20	Number and proportion of patients (from #2) with confirmed NSCLC	184	56%	52%	60%	62%	0%	•	93%	NLCA	2011
Throughput and	21	Number and proportion of patients (from #2) with confirmed SCLC	40	12%	9%	16%	12%	0%	o	100%	NLCA	2011
pathology	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS	21	11%	8%	17%	19%	0%	○ ♦	79%	NLCA	2011
patriology	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%	◆	100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%	♦ 0	97%	HES	2011
	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%	○◆	100%	CWT	2012/13 Q2
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%	0.	100%	CWT	2012/13 Q2
Waiting times	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%	•••	46%	CWT	2011/12
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%	• •	76%	CWT	2011/12
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%	↑ •	100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%	0 •	100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%	•0	38%	NLCA	2011
Drastics	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%	• O	45%	NLCA	2011
Practice	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease	40	48%	38%	59%	53%	0%	○ ◆	100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%	O	100%	NLCA	2011
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%	•	100%	NLCA	2011
Outcome	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%	•	68%	PBR SUS	2011/12
Outcomes and Recovery	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57	•	1.49	NLCA	2011
and Recovery	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40	• •	2.67	NLCA	2011
Patient	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%	.	100%	CPES	2011/12
Experience -	40	N		n/a				0%		78%	CPES	2011/12
CPES (8)	41	Number of survey questions and % of those questions scoring red and green (7) With the control of the contro	1 0	n/a				0%	1	69%	CPES	2011/12

Profiles... why?



					Percenta	ge or rate		Tr	ust rate or percentage compared to Eng	land	1	
Section	#	Indicator	No. of patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41	→ •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	329				191	1	• •	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				10	0	(O	31	NLCA	2011
	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010
6	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%	•	100%	NCDR	2010
s y 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%	○	46%	NCDR	2010
phics newly ents, 2	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	•	34%	NCDR	2010
Demographics (based on newly nosed patients, 2	8	Male patients (from #1)	161	53%	47%	58%	55%	43%	0 •	72%	NCDR	2010
ed of p	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	▼	100%	NLCA	2011
Derr (bas	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%	• •	68%	NLCA	2011
agn	11	Number a									NLCA	2011
7	12	Number a	_				_		_		NLCA	2011
	13	Proportion • Assess and benchmar	k a v	vid	o ra	naa	Ωf	iní	formation at		NLCA	2011
	14	Peer revie A33C33 and Dentilinar	n a v	VIU	c la	uge	UI		ormation at		NCPR	2010/1
	15	Peer revit				_					NCPR	2010/1
Specialist Team	16	Peer revie									NCPR	2010/1
ream	17	Peer revie or conjugation love									NCPR	2010/1
	18	Peer revit organisation level								-	NLCA	2011
											NLCA	2011
	19	Number c								-	CWT	_
	19 20									-		_
0 1		Number a		o n	non	· of	on	0 F	ganication	-	CWT	2010/1
and		Number a	sse	ssn	nen	t of	an	or	ganisation	- - -	CWT NLCA	2010/1 2011
0 1	20 21	Number a Number a fat a glance, a	sse	ssn	nen	t of	an	or	ganisation	- - -	CWT NLCA NLCA	2010/1 2011 2011
and	20 21 22	Number a Num	sse	ssn	nen	t of	an	or	ganisation	- - - -	CWT NLCA NLCA NLCA	2010/1 2011 2011 2011
and	20 21 22 23 24	Number a Num	ISSE:	ssn	nen	t of	an	or	ganisation	- - - - -	CWT NLCA NLCA NLCA NLCA HES	2010/1 2011 2011 2011 2011 2011
	20 21 22 23 24 25	Number a Number a Number a Number a Sumber a Sum	ISS e :	ssn	nen	t of	an	or	ganisation	-	CWT NLCA NLCA NLCA NLCA HES CWT	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology	20 21 22 23 24 25 26	Number a O2 2012/ Q2 2012/							ganisation		CWT NLCA NLCA NLCA NLCA NLCA CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13
and pathology	20 21 22 23 24 25 26 27	Number a Stimate O2 2012/ O2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%	ganisation	46% 76%	CWT NLCA NLCA NLCA NLCA HES CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1
and pathology	20 21 22 23 24 25 26 27	Number a Number a Number a Number a Number a Stimated Cu2 2012/ Cu2 2012/ Curgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental]			21% 19%	30% 33%	24% 39%	4% 0%	ganisation	76%	CWT NLCA NLCA NLCA NLCA NLCA CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1
and pathology	20 21 22 23 24 25 26 27 28 29	Number a Number a Number a Number a Number a Sumber a Sum	103	25% 25%	21% 19% 78%	30% 33% 100%	24%	4%	ganisation		CWT NLCA NLCA NLCA NLCA NLCA CWT CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2012/13
and pathology	20 21 22 23 24 25 26 27 28 29	Number a Number a Number a Number a Number a Stimated Cu2 2012/ Cu2 2012/ Curgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental]	103 34 14 174	25% 25% 100% 53%	21% 19% 78% 47%	30% 33% 100% 58%	24% 39% 99% 60%	4% 0% 91% 36%	•	76% 100% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011/13
and pathology	20 21 22 23 24 25 26 27 28 29 30 31	Number a Num	103 34 14	25% 25% 100%	21% 19% 78%	30% 33% 100% 58% 22%	24% 39% 99%	4% 0% 91%	•	76% 100%	CWT NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2012/13 2011 2011/1 2011/1
and pathology	20 21 22 23 24 25 26 27 28 29 30 31 32	Number a Num	103 34 14 174 50	25% 25% 100% 53% 17% 26%	21% 19% 78% 47% 13% 20%	30% 33% 100% 58% 22%	24% 39% 99% 60% 16% 21%	4% 0% 91% 36% 0%	• • •	76% 100% 100% 38% 45%	CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
and pathology /aiting times	20 21 22 23 24 25 26 27 28 29 30 31 32 33	Number a Num	103 34 14 174 50 48	25% 25% 100% 53% 17%	21% 19% 78% 47% 13% 20% 38%	30% 33% 100% 58% 22% 33%	24% 39% 99% 60% 16% 21% 53%	4% 0% 91% 36% 0%	• • • • • • • • • • • • • • • • • • • •	76% 100% 100% 38% 45% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2012/13 2011 2011 2011 2011 2011 2011 2011
and pathology /aiting times	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Number a Number a Number a Number a Number a Number a Stimatec Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC with stage I and II disease	103 34 14 174 50 48 40 27	25% 25% 100% 53% 17% 26% 48%	21% 19% 78% 47% 13% 20%	30% 33% 100% 58% 22% 33% 59%	24% 39% 99% 60% 16% 21%	4% 0% 91% 36% 0% 0%	• • • • • • • • • • • • • • • • • • • •	76% 100% 100% 38% 45%	CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011 2011 2011 2011 2011
and pathology /aiting times	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Number a Num	103 34 14 174 50 48 40 27 28	25% 25% 100% 53% 17% 26% 48% 68% 58%	21% 19% 78% 47% 13% 20% 38% 52% 44%	30% 33% 100% 58% 22% 33% 59% 80% 71%	24% 39% 99% 60% 16% 21% 53% 68% 55%	4% 0% 91% 36% 0% 0% 0%		76% 100% 100% 38% 45% 100% 100%	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology laiting times Practice Outcomes	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number a Num	103 34 14 174 50 48 40 27 28 23,053	25% 25% 100% 53% 17% 26% 48% 68% 58% 41%	21% 19% 78% 47% 13% 20% 38% 52% 44%	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 21% 53% 68% 55% 32%	4% 0% 91% 36% 0% 0% 0% 0%		76% 100% 100% 38% 45% 100% 100% 68%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT ALCA NLCA NLCA NLCA NLCA NLCA NLCA PBR SUS	2010/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
and pathology /aiting times Practice Outcomes	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number a Sumbar a Number a Number a Sumbar a Sum	103 34 14 174 50 48 40 27 28 23,053	25% 25% 100% 53% 17% 26% 48% 68% 58% 41%	21% 19% 78% 47% 133% 20% 38% 52% 44% 0.82	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32%	4% 0% 91% 36% 0% 0% 0% 0% 15%		76% 100% 100% 38% 45% 100% 100% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times Practice Outcomes and Recovery	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number a Number a Number a Number a Number a Number a Stimatec Q2 2012/ Q2 2012/ Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2) excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	103 34 14 174 50 48 40 27 28 23,053 176 34%	25% 25% 100% 53% 17% 26% 48% 68% 58% 41% 0.95	21% 19% 78% 47% 13% 20% 38% 52% 44% 0.82	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32% 1.0	4% 0% 91% 36% 0% 0% 0% 0% 15% 0.57		76% 100% 38% 45% 100% 100% 100% 68% 1.49 2.67	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times Practice Outcomes and Recovery Patient	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number a Num	103 34 14 174 50 48 40 27 28 23,053	25% 25% 100% 53% 17% 26% 48% 68% 58% 0.95	21% 19% 78% 47% 13% 20% 38% 52% 44% 0.82	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32%	4% 0% 91% 36% 0% 0% 0% 0% 057 0.57 0.40		76% 100% 100% 38% 45% 100% 100% 100% 68% 1.49 2.67	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times Practice Outcomes nd Recovery	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number a Number a Number a Number a Number a Number a Stimatec Q2 2012/ Q2 2012/ Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2) excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	103 34 14 174 50 48 40 27 28 23,053 176 34%	25% 25% 100% 53% 17% 26% 48% 68% 58% 41% 0.95	21% 19% 78% 47% 13% 20% 38% 44% 41% 0.82 0.97	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32% 1.0	4% 0% 91% 36% 0% 0% 0% 0% 15% 0.57		76% 100% 38% 45% 100% 100% 100% 68% 1.49 2.67	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/ 2011 2011 2011 2012/1: 2012/1: 2011/1: 2011/1: 2011 2011 2011 2011 2011 2011 2011 20

Lung profiles – process



- Aim: Benchmark and assess trust/MDT for commissioning & clinical review
- Published March 2013 (developed from similar Breast/Colorectal profiles published Dec 2011, Feb 2013)
- Data cancer registry, CWT, NLCA, CPES, HES, Peer Review
- Roughly half indicators generic, half specialist.
- Specialist indicators largely drawn from NLCA
- Indicators Incorporate Clinical Lines of Enquiry
- A NCIN / Thames Cancer Registry co-production
- Hosted in the Cancer Commissioning Toolkit

Profile anatomy



				Percentage or rate Trust rate or percentage compared to Englan								
Section		Indicator	patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				20	41	• •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	329				19	1	•	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				1	0	•	31	NLCA	2011
	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010
6	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010
s y 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%	○ ◆	46%	NCDR	2010
Demographics (based on newly diagnosed patients, 20	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	• O	34%	NCDR	2010
rap on n atie	8	Male patients (from #1)	161	53%	47%	58%	55%	43%	0 •	72%	NCDR	2010
ed o	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	(A)	100%	NLCA	2011
Derr bas nose	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%	• •	68%	NLCA	2011
iagn (11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%	O.	30%	NLCA	2011
- 0	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%	Q	80%	NLCA	2011
		Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%	O	100%	NLCA	2011
	14	Peer review: Doe			_						NCPR	2010/
Specialist Team		Peer review: Prog Peer review: are	ţ.	NU	mbe	ers,	97		Spine chart &	S	Sour	CA
Tealli		Number and prop descriptions		rate	26 2	and	99		-		Jour	UU.
Team	18 19	Number and prop Number of urgent descriptions	-		es, a		9% 29:		range of data	14	_	
hroughput	18 19 20	Number and prop descriptions	-		•		99 29 29 29		-	<u> </u>	_	
hroughput and	18 19 20 21	Number and prop Number of urgenl Number and prop (444)	-		es, a para		9% 293 2% 2% 9%		-	(<u>K</u> 16070	_	ites
hroughput and	18 19 20 21 22	Number and prop Number of urgen Number and prop Number and prop Number and prop	-		•		9% 29; 29 29 99 77%	U%	-	(<u>k</u> <u>K</u> 16070	Da	ites
hroughput	18 19 20 21 22 23	Number and prop Number of urgenl Number and prop	C	om	para 64%	ator	9%	U% 0%	range of data	(k <u>k</u> 1607 79%	NLCA	201°
hroughput and	18 19 20 21 22 23 24	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis	C(om 69%	para 64%	ator:	99 779	0% 0% 52%	range of data	160% 79%	NLCA NLCA	201 201 201 201
hroughput and	18 19 20 21 22 23 24 25	Number and prop Number of urgenl Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental]	228 94	69% 47%	para 64% 40%	74% 54%	9% 77% 37%	0% 0% 52% 2%	range of data	79% 100% 100%	NLCA NLCA HES	201 201 201 201 2012/13
hroughput and pathology	18 19 20 21 22 23 24 25 26	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	228 94 135	69% 47% 96%	para 64% 40% 92%	74% 54% 98%	99 779 379 979	0% 0% 52% 2% 88%	range of data	100% 79% 100% 97%	NLCA NLCA HES CWT	201- 201- 201- 2012/13 2012/13
hroughput and pathology	18 19 20 21 22 23 24 25 26 27	Number and prop Number of urgent Number and prop Number and prop Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	228 94 135 15	69% 47% 96% 73%	64% 40% 92% 52%	74% 54% 98% 87%	99 779 379 979 809	0% 0% 52% 2% 88% 0%	range of data	100 /o 79% 100% 97% 100% 100%	NLCA NLCA HES CWT	201 201 201 201 2012/13 2012/13 2011/
nroughput and pathology	18 19 20 21 22 23 24 25 26 27 28	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	228 94 135 15	69% 47% 96% 73% 25%	64% 40% 92% 52% 21%	74% 54% 98% 87% 30%	9% 77% 37% 97% 80% 24%	0% 0% 52% 2% 88% 0% 4%	range of data	79% 100% 97% 100% 100% 46%	NLCA NLCA NLCA HES CWT CWT	201 201 201 201 2012/13 2012/13 2011/ 2011/
nroughput and pathology	18 19 20 21 22 23 24 25 26 27 28 29	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seem within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referrals for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental]	228 94 135 15 103 34	69% 47% 96% 73% 25% 25%	64% 40% 92% 52% 21%	74% 54% 98% 87% 30% 33%	9% 77% 37% 97% 80% 24% 39%	0% 52% 2% 88% 0% 4%	range of data	100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA CWT CWT CWT	201 201 201 2012/13 2012/13 2011/1 2011/1 2011/1
hroughput and pathology	18 19 20 21 22 23 24 25 26 27 28 29 30	Number and prop Number of urgenl Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat	228 94 135 15 103 34	69% 47% 96% 73% 25% 25% 100%	64% 40% 92% 52% 21% 19% 78%	74% 54% 98% 87% 30% 33% 100%	9% 77% 37% 97% 80% 24% 39% 99%	0% 0% 52% 2% 88% 0% 4% 0% 91%	range of data	79% 100% 97% 100% 100% 46% 76% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT	201- 201- 201- 201- 2012/13 2012/13 2011/ 2011/ 2012/13 2012/13
hroughput and aathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	228 94 135 15 103 34 14	69% 47% 96% 73% 25% 25% 100%	64% 40% 92% 52% 21% 19% 78% 47%	74% 54% 98% 87% 30% 33% 100% 58%	9% 77% 37% 97% 80% 24% 39% 99% 60%	0% 0% 52% 2% 88% 0% 4% 0% 91% 36%	range of data	79% 100% 97% 100% 100% 46% 76% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA	2011/13 2011/13 2012/13 2012/13 2012/13 2011/1 2011/1 2012/13 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/
hroughput and pathology	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC	228 94 135 15 103 34 14 174 50	69% 47% 96% 73% 25% 25% 100% 53%	64% 40% 92% 52% 21% 78% 47%	74% 54% 98% 87% 30% 100% 58%	99 779 379 979 809 249 399 999 609 169	0% 52% 2% 88% 0% 4% 0% 91% 36%	range of data	100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA	2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
hroughput and aathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC	228 94 135 15 103 34 14 174 50	69% 47% 96% 25% 25% 100% 53% 17% 26%	64% 40% 92% 52% 21% 19% 47% 13% 20%	74% 54% 98% 87% 30% 33% 100% 58% 22%	99 779 379 979 809 249 399 999 609 169 219	0% 52% 2% 88% 0% 4% 0% 91% 36% 0%	range of data	100% 100% 97% 100% 97% 100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT CWT NLCA NLCA NLCA	2011/ 2011/ 2012/13 2012/13 2012/13 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/
hroughput and aathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Number and prop Number of urgenl Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Oz 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Oz 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Oz 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	228 94 135 15 103 34 14 174 50 48	69% 47% 96% 25% 25% 100% 53% 17% 26% 48%	64% 40% 52% 52% 21% 19% 78% 47% 43% 20% 38%	74% 54% 98% 87% 30% 33% 100% 58% 22% 33% 59%	99 779 379 979 809 249 399 999 609 169 219 539	0% 52% 2% 88% 0% 4% 91% 36% 0% 0%	range of data	79% 100% 97% 100% 97% 100% 46% 76% 100% 38% 45% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA	2011/13 2011/13 2012/13 2012/13 2012/13 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
hroughput and pathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] O2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks O2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] O2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion of patients (from #2) with confirmed SCLC with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	228 94 135 15 103 34 14 174 50 48 40 27	69% 47% 96% 73% 25% 25% 100% 53% 17% 26% 48%	64% 40% 92% 52% 21% 19% 47% 13% 20% 38% 52% 44%	74% 54% 98% 87% 30% 100% 58% 22% 33% 59%	9% 77% 37% 97% 80% 24% 39% 99% 60% 16% 21% 53% 68%	0% 52% 2% 88% 0% 4% 91% 36% 0% 0%	range of data	100 / 79% 100% 97% 100% 100% 100% 46% 76% 100% 100% 38% 45% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA	2011/13 2012/13 2012/13 2012/13 2012/13 2011/1 2011
hroughput and pathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Oz 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Oz 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Oz 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with confirmed SCLC, receiving chemotherapy	228 94 135 15 103 34 14 174 50 48 40 27	69% 47% 96% 73% 25% 25% 100% 53% 48% 68% 58%	64% 40% 92% 52% 21% 19% 47% 43% 20% 38% 52% 444% 41%	74% 544% 98% 87% 30% 33% 100% 100% 59% 80% 71% 41%	99 779 379 979 809 249 399 999 609 169 219 539 689	0% 52% 2% 88% 0% 4% 0% 91% 36% 0% 0% 0%	range of data	100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2011/12 2011/12 2012/13 2012/13 2012/13 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
nroughput and pathology siting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with sufficiency and proportion confirmed SCLC receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053	69% 47% 96% 73% 25% 100% 53% 17% 26% 48% 68% 58%	64% 40% 92% 52% 21% 19% 78% 47% 13% 20% 38% 52% 44% 41% 0.82	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 779 379 979 809 249 399 999 609 169 219 539 689	0% 52% 2% 88% 0% 4% 91% 36% 0% 0% 0%	range of data	100% 97% 100% 97% 100% 46% 76% 100% 38% 45% 100% 100% 68%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA PBR SUS	2011/ 2011/ 2012/13 2012/13 2012/13 2011/
hroughput and pathology aiting times Practice Dutcomes d Recovery	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with sufficiency and proportion confirmed SCLC receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053	69% 47% 96% 25% 25% 25% 100% 53% 48% 68% 68% 41% 0.95	64% 40% 92% 52% 21% 19% 78% 47% 43% 20% 38% 52% 44% 0.82	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 779 379 979 809 249 399 999 609 169 219 539 689	0% 52% 2% 88% 0% 4% 0% 36% 0% 0% 0% 0% 0%	range of data	100 / 79% 100 / 79% 100 / 97% 100 / 46% 76% 100 / 46% 100 / 38% 45% 100 / 100 / 100 / 68% 1.49	NLCA NLCA NLCA HES CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2011/ 2011/ 2012/13 2012/13 2012/13 2011// 2011/
hroughput and pathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number and prop Number of urgent Number and prop Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Oz 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Oz 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Oz 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) with confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC No. and proportion of patients (from #2) with confirmed SCLC with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with confirmed SCLC receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053 176 34%	69% 47% 96% 73% 25% 100% 53% 48% 68% 58% 41% 0.95	64% 40% 92% 52% 21% 19% 47% 43% 520% 44% 41% 0.822 0.97	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 779 379 979 809 249 399 999 609 169 211 539 688 559 329 1.1	0% 52% 2% 88% 0% 91% 36% 0% 0% 0% 0% 0%	range of data	100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA NLCA CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2011/1 20

Profile anatomy



												_	
				No. of		Percent	age or rate		Tr	ust rate or percentage compared to E	ingland		
Section	#	Indicator		patients/ cases or value	Trust	Lower 95% confidence limit		England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [_	• •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	Size – no.	nati	ien	ts d	liadr	105	ed	•	585	NLCA	2011
	3			. pat		to a	uagi	100	U	≪	31	NLCA	2011
	5	Patients (from #1) aged 70* Patients (from #1) with recorded ethnicity		205	07%	049	// Q80	6 93%	66%		100%	NCDR NCDR	2010
aphics newly ients, 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British		293	1 31/0	01 347	/61 30 /	61 93 / <u>6</u>	0%		46%	NCDR	2010
ics swly ts, 2	7	Patients (from #1) who are Income Deprived (2)	Patier	at do	mo	ara	nhic	• ·	7%	•	34%	NCDR	2010
aph n ne itien	8	Male patients (from #1)	— rauti	IL UE		yı a	Pille	, 5	43%	0	72%	NCDR	2010
ed o	9	Number and proportion of patients (from #2) with a stage assigned		4.5			_ /DO	6	36%	(♦)	100%	NLCA	2011
Demographics (based on newly gnosed patients, 20	10	Number and proportion of patients, excluding SCLC, with stage I or II	assign (inclu	udina	3 S1	iade	3/PS	6	10%	• •	68%	NLCA	2011
liagr	11	Number and proportion of patients, excluding SCLC, with a stage IIIA	assign					<u>0</u>	4%	0	30%	NLCA	2011
0	12	Number and proportion of patients, excluding SCLC, with a stage IIIB	and IV assigned	167	58%	53%	649	62%	13%		80%	NLCA NLCA	2011
	13	Peer review Does the specialist team have full membershin? (3)		286	8/% Vac	839	Al Gire	% X9%	5%		100%		2011
	15	Pear radials Tribe the creatainst team rade thi mannarchity (1)						•		•		NCPR NCPR	2010/1
Specialist	13												
	16	Specialist team -	Poor Roy	iow (on	COL	ne s	has		VS coverage			
Team	16 17	Specialist team -	Peer Rev	iew (con	cer	ns a	and	CI	VS coverage		NCPR	2010/1
	16 17 18	Specialist team -	Peer Rev	iew (CON	icer	'ns a	and	CI	VS coverage	I100%		2010/1
	16 17 18	Pe Pe Specialist team — Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer	Peer Rev	iew (CON	icer	'ns a	and	C	VS coverage	853	NCPR	2010/1 2010/1 2011
Team	16 17 18 19 20	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati		406	63%	57%	689	293	0%		853 93%	NCPR NCPR	2010/1 2010/1 2011
Team	16 17 18 19 20 21	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati		406	63%	57%	689	293	0%		100%	NCPR NCPR NLCA CWT NLCA NLCA	2010/1 2010/1 2011/1 2010/1 2011 2011
Team Throughput and	21 22	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati		406	63%	57%	689	293	0%		100% 79%	NCPR NCPR NLCA CWT NLCA NLCA NLCA	2010/1 2010/1 2011/1 2010/1 2011 2011 20
Team Throughput and	16 17 18 19 20 21 22 23	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati	ut and pa	406	63%	/ – [patie	293	0%		100%	NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2010/1 2011/1 2011 201
Team Throughput and	21 22	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati	ut and pa	406	Ogy	57% 7 — F 5 40%	patie	293	0%		100% 79%	NCPR NCPR NCPR NCA NCA NLCA NLCA NLCA NLCA NLCA HES	2010/1 2010/1 2011/1 2010/1 2011 2011 20
Team Throughput and	21 22 23 24 25	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [expertication of pation of pati	ut and pa	206 406 1 thol (Ogy 47%	7 — F	Datie 54%	293 ent l	0 0 2%	eakdown	100% 79%	NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA HES	2010/1: 2010/1: 2011/1: 2011/1: 2011 2011 2011 2011 2011 2011 2012/13 (
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [expertication of pation of pati	ut and pa	206 406 1 thol (Ogy 47%	7 — F	Datie 54%	293 ent l	0 0 2%	eakdown	100% 79%	NCPR NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA NLCA CWT CWT	2010/1: 2010/1: 2011/1: 2010/1: 2011 2011 2011 2011 2011 2011 2012/13: 2012/13:
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper	ut and pa	206 406 1 thol (Ogy 47%	7 — F	Datie 54%	293 ent l	0 0 2%	eakdown	100% 79%	NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA HES	2010/1: 2010/1: 2011/1: 2011/1: 2011 2011 2011 2011 2011 2011 2012/13: 2012/13: 2011/1:
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [expertication of pation of pati	ut and pa	206 406 1 thol (Ogy 47%	7 — F	Datie 54%	293 ent l	0 0 2%	eakdown	100% 79%	NCPR NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT	2010/1: 2010/1: 2011/1: 2011/1: 2011 2011 2011 2011 2011 2012/13: 2012/13: 2011/1: 2011/1:
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [expertication of pation of pati	ut and pa	206 406 1 thol (Ogy 47%	7 — F	Datie 54%	293 ent l	0 0 2%	eakdown	100% 79% 100% 97%	NCPR NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team Throughput and pathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) eeen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 wo 02 20 Urgen Waiting times pe Caset No. and proportion of patients (from #2) receiving surgery, chemothers. No. and proportion of patients (from #2) excluding confirmed	ut and pa imental eeks rformanc apy and/or radiotherapy scl.c	1406 1406 135 1406 135 1417	Ogy 47% d c	7 — F	Datie 549 7 ersi 7 89	293 ent 37% 37% 97% 60% 60% 16%	2% 88% de 91% 36% 0%	eakdown	100% 79% 100% 97% 1101%	NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT NLCA NLCA NLCA	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati Estimated proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 we 02 20 Urgen Cases 02 2012/13: First treatment began within 31 days or decision to treat No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) with confirmed NSC	ut and pa imental eeks rformanc apy and/or radiotherapy scl.c	1406 1406 135 1406 135 1417	Ogy 47% d c	7 — F	Datie 549 7 ersi 7 89	ent 293 ent 37% 37% 97% 60% 60% 16% 21%	2% 88% de 91% 36% 0%	eakdown	100% 79% 100% 97% 1100% 1100% 38% 45%	NCPR NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2010/1 2011/1 2011 2011 20
Team Troughput and pathology aiting times	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 widely great to the control of the control o	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage and	206 406 1 thol (Ogy 47% d c	7 — F	Datie 549 7 ersi 7 89	293 ent 37% 37% 97% 97% 60% 60% 60% 621% 53%	2% 88% de 91% 36% 0% 0%	eakdown	100% 79% 100% 97% 1100% 1100% 38% 45% 100%	NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2010/1 2010/1 2010/1 2010/1 2011/1 2011 201
Team hroughput and pathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati Estimated proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 we 02 20 Urgen Cases 02 2012/13: First treatment began within 31 days or decision to treat No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) with confirmed NSC	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage and	1406 1406 135 1406 135 1417	Ogy 47% d c	7 — F	Datie 549 7 ersi 7 89	ent 293 ent 37% 37% 97% 60% 60% 16% 21%	2% 88% de 91% 36% 0%	eakdown	100% 79% 100% 97% 1100% 1100% 38% 45%	NCPR NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team hroughput and pathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) each by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 we 02 20 Urgen Waiting times pe 02 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) with confirmed NSC. No. and proportion resected of patients (from #2), excluding confirmed SCL. No. and proportion of patients (from #2) with confirmed SCL. No. and proportion of patients (from #2) with confirmed SCL. No. and proportion of patients (from #2) with confirmed SCL.	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage and	1406 1406 135 1406 135 1417	Ogy 47% d c	7 — F	Datie 549 7 ersi 7 89	293 ent 37% 37% 97% 97% 60% 60% 60% 621% 53%	2% 88% de 91% 36% 0% 0%	eakdown tection rates	100% 79% 100% 97% 1100% 100% 38% 45% 100% 100%	NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team Troughput and pathology aiting times Practice	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) each by CNS (5). Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 wc Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother. No. and proportion resected of patients (from #2) excluding confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed SCL. No. and proportion of patients (from #2), excluding confirmed SCL. No. and proportion of patients (from #2) with confirmed SCL. First outpatient appointments and proportion of all outpatient appointments.	ut and pa	thology of the sean of the sea	99y 47% d c	7 - F	Datie 0	293 ent 37% 97% 97% 6 60% 6 16% 6 21% 6 53% 6 68% 7 560	2% 88% de 91% 36% 0% 0%	eakdown	100% 79% 100% 97% 100% 100% 38% 45% 100% 100% 68%	NCPR NCPR NCPR NICA CWT NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team Troughput and pathology aiting times Practice	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) each by CNS (5). Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 wc Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother. No. and proportion resected of patients (from #2) excluding confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed SCL. No. and proportion of patients (from #2), excluding confirmed SCL. No. and proportion of patients (from #2) with confirmed SCL. First outpatient appointments and proportion of all outpatient appointments.	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage and	thology of the sean of the sea	99y 47% d c	7 - F	Datie 0	293 ent 37% 97% 97% 6 60% 6 16% 6 21% 6 53% 6 68% 7 560	2% 88% de 91% 36% 0% 0%	eakdown tection rates	100% 79% 100% 97% 1100% 100% 38% 45% 100% 100%	NCPR NCPR NCPR NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2010/1 2010/1 2010/1 2010/1 2011/1 20
Team Throughput and pathology aiting times Practice Outcomes	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5). Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati Estimated proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 wid Q2 20 Urgen Cases: Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemothers No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) with confirmed NSC No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2) with confirmed SCL receivin Land proportion of patients (from #2) with confirmed SCL receiving the patients of patients (from #2) and proportion of patients (from #2) and proportion of patients (from #2) with confirmed SCL receiving the patients (from #2) and proportion of patients (from #2) with confirmed SCL receiving the patients (from #2) and proportion of patients (from #2) with confirmed SCL receiving the patients (from #2) and proportion of patients (from #2) with confirmed SCL receiving the patients (from #2) and proportion of patients (from #2) with confirmed SCL receiving the patients (from #2) and proportion of patients (from #2) with confirmed SCL receiving the patients (from #2) and proportion of patients (from #2) with confirmed SCL receiving the patients (from #2) and proportion of patients (from #2) with catce (from #2) and proportion of patients (from #2) with catce (from #2) and proportion of patients (from #2) with catce (from #2) and proportion of patients (from #2) and proportion of patients (from #2) and proportion of patients (from #2) and proportion of	ut and pa	thology of the sean of the sea	99y 47% d c	7 - F	Datie 0	293 ent 37% 97% 97% 6 60% 6 16% 6 21% 6 53% 6 68% 7 560	2% 88% de 91% 36% 0% 0%	eakdown tection rates	100% 79% 100% 97% 1100% 1100% 38% 45% 100% 100% 100% 100%	NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/11 2010/11 2010/11 2011 2011 2011 2
Tream Throughput and pathology /aiting times Practice Outcomes and Recovery	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5). Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 wc 02 20 Urgen Cases 02 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother. No. and proportion resected of patients (from #2) excluding confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed SCI. No. and proportion resected of patients (from #2), excluding confirmed SCI. No. and proportion of patients (from #2) with confirmed SCI. No. and proportion of patients (from #2) with confirmed SCI. The section of patients (from #2) with confirmed SCI. No. and proportion of patients and proportion of all outpatient appointments and proportion of all outpatient appointments and proportion of patients survival in days and adjusted hazard ratio for morta NLCA: Median survival in days and adjusted hazard ratio for morta NLCA: Proportion of patients surviving at one year and adjusted oc	ut and pa imental eeks rformanc apy and/or radiotherapy SCLC LC .C. with stage I and I g chemotherapy Outcome dignity (6) Dation	thologian in the sean in the s	Ogy 47% d c 53% pr	7 - F 0 40% 0 000 0 47% acti	patie versi	293 ent 37% 97% 97% 6 60% 6 16% 6 21% 6 53% 6 68% 7 560	2% 88% de 91% 0% 0% 0%	eakdown tection rates	100% 79% 100% 97% 1100% 1100% 38% 45% 100% 100% 100% 100%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/11 2010/11 2010/11 2011 2011 2011 2

Profiles – detail (1)



Section	#	Indicator
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)
Size	2	Number of NLCA patients - lung cancer
	3	Number of NLCA patients - mesothelioma
	4	Patients (from #1) aged 70+
6	5	Patients (from #1) with recorded ethnicity
s 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British
phics newly ents, 2	7	Patients (from #1) who are Income Deprived (2)
Demographics (based on newly nosed patients, 2	8	Male patients (from #1)
Demogra (based on nosed pati	9	Number and proportion of patients (from #2) with a stage assigned
bas ose	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned
Demo (based diagnosed	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned
ē	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned
	13	Proportion of patients (from #2) with a Performance Status assigned

Profiles – detail (2)



	14	Peer review: Does the specialist team have full membership? (3)
Oncololist	15	Peer review: Proportion of peer review indicators met
Specialist Team	16	Peer review: are there immediate risks? (4)
realii	17	Peer review: are there serious concerns? (4)
	18	Number and proportion of patients (from #2) seen by CNS (5)
	19	Number of urgent GP referrals for suspected cancer
	20	Number and proportion of patients (from #2) with confirmed NSCLC
Throughput	21	Number and proportion of patients (from #2) with confirmed SCLC
and pathology	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS
patriology	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis
	24	Estimated proportion of tumours with emergency presentations [experimental]

Profiles – detail (3)



	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer
Waiting times	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]
	29	Q2 2012/13: First treatment began within 31 days of decision to treat
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC
Practice	32	No. and proportion resected of patients (from #2) with confirmed NSCLC
Practice	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy

Profiles – detail (4)



Outcomes	36	First outpatient appointments and proportion of all outpatient appointments					
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality					
and Recovery	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year					
Patient	39	Patients surveyed & % reporting always being treated with respect & dignity (6)					
Experience -	40	Number of survey questions and % of those questions scoring red and green (7)	% Red				
CPES (8)	41	indifficer of survey questions and % of those questions scoring red and green (7)	% Green				

Lung profiles overview



- Contains many relevant process, clinical, and outcome indicators – but new data gives new opportunities
- (The NLCA adds a great deal of clinical value)
- Profile format is strong at assessing and benchmarking organisations (but not the whole story)

Specialist Lung profiles?



- Use a profile format to assess and benchmark organisations (?)
- Some challenges:
 - Only include cases referred for surgery?
 - Can we separate local/specialist cases at same provider?
 - Need a good understanding of how the pathway is represented in the data
- What are the important process, clinical and outcome variables?



Using information to improve quality & choice

www.ncin.org.uk